Overview
The UGT1A1 gene handles the body’s primary cleanup route for bilirubin, the yellow pigment produced when red blood cells recycle normally. In Phase II liver metabolism, UGT1A1 attaches glucuronic acid so bilirubin dissolves smoothly into bile.
In ~10% of adults, reduced transcription from the common *28 variant produces Gilbert’s syndrome—mild, harmless rises in unconjugated bilirubin alongside crucial dosing implications for oncology agents such as irinotecan.
2q37.1 (Chromosome 2)
Detoxification & Bilirubin
Phase II Glucuronidation Enzyme
Bilirubin clearance & PGx
Function of UGT1A1
UGT1A1 serves dual duty: clearing endogenous bilirubin and steroid hormones while conjugating active drug metabolites such as SN-38 (the potent cytotoxic metabolite of irinotecan).
Key Aspects:
🟡 Benign Gilbert’s Syndrome (*28/*28)
With ~30% enzyme capacity, fasting, illness, intense workouts, or sleep debt briefly bump indirect bilirubin slightly—clinically harmless and even epidemiologically linked with antioxidant benefits.
💊 Irinotecan & Atazanavir Safety
In oncology, reduced SN-38 clearance in *28/*28 or *6/*6 patients elevates severe neutropenia and diarrhea risk unless starting irinotecan doses are lowered.
🧬 Genetic Variants (SNPs)
Promoter repeat and coding variants alter UGT1A1 glucuronidation throughput across populations:
2:233760233
Seven TA repeats instead of six weaken promoter activity (~70% drop), explaining most European Gilbert’s cases and CPIC irinotecan warnings.
~30-35% (Europe)
2:233760498
Decreases enzymatic glucuronidation efficiency by ~50-70% in homozygotes; clinically critical across East Asian ancestry.
~15-20% (East Asia), <2% (Europe)
Practical Significance
✅ Strategies & Guidance
- Pre-Chemotherapy Screening: Ensure UGT1A1 genotyping is reviewed before initiating high-dose irinotecan or sacituzumab govitecan.
- Avoid Prolonged Fasting: Regular balanced meals prevent needless unconjugated bilirubin spikes or mild scleral yellowing.
- Reassuring Lab Differentiation: Elevated isolated indirect bilirubin with completely normal ALT/AST/GGT and ultrasound confirms benign physiology.
⚠️ Clinical Notes & Risks
- Oncology Drug Toxicity: Standard irinotecan dosing in *28/*28 carries FDA/CPIC warnings for grade 3–4 neutropenia.
- Cosmetic Jaundice on HIV Therapy: Protease inhibitor atazanavir blocks UGT1A1 competitively, causing reversible benign yellowing.
- Rule Out Hemolysis First: Persistent jaundice always merits standard CBC/reticulocyte check initially.
📚 Data Sources
- OMIM: #191740 (UDP-Glycosyltransferase 1 Family, Polypeptide A1)
- dbSNP: rs8175347 (*28), rs4148323 (*6)
- CPIC Guideline: UGT1A1 Genotype and Irinotecan / Atazanavir Therapy
- PharmGKB: Clinical Annotations Level 1A for UGT1A1
Last Update: November 2026
Related Genes in Detoxification
F5
F5 encodes coagulation factor V. The Leiden mutation is one of the most common hereditary thrombophilias....
GSTP1
GSTP1 is an important detoxification enzyme that neutralizes toxins and drugs by binding them to glutathione....
NAT2
NAT2 drives Phase II liver acetylation of drugs (isoniazid, sulfonamides) and heterocyclic amines. Variants divide individuals…